FMP

FMP

Enter

PYXS - Pyxis Oncology, Inc.

Analysis of Pyxis Oncology, Inc.(PYXS), Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of t

photo-url-https://financialmodelingprep.com/image-stock/PYXS.png

Pyxis Oncology, Inc.

PYXS

NASDAQ

Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

3.42 USD

-0.24 (-7.02%)

page loading card

Upgrades & Downgrades

We are unable to load this data!

fmp-logo

Price PriceTargets

We are unable to load the data!

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep